<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240619121131&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240619121131&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 19 Jun 2024 16:11:33 +0000</lastbuilddate>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Perinatal depression and incident maternal cardiovascular disease: a neglected association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38889803/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 18:ehae340. doi: 10.1093/eurheartj/ehae340. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38889803/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38889803</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae340>10.1093/eurheartj/ehae340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38889803</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Amani Meaidi</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perinatal depression and incident maternal cardiovascular disease: a neglected association</dc:title>
<dc:identifier>pmid:38889803</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae340</dc:identifier>
</item>
<item>
<title>Perinatal depression and risk of maternal cardiovascular disease: a Swedish nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38889798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Women with PND are at higher risk of CVD in middle adulthood. Reproductive history, including PND, should be considered in CVD risk assessments of women.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 18:ehae170. doi: 10.1093/eurheartj/ehae170. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Increasing evidence suggests that some reproductive factors/hazards are associated with a future risk of cardiovascular disease (CVD) in women. While major (non-perinatal) depression has consistently been associated with CVD, the long-term risk of CVD after perinatal depression (PND) is largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A nationwide population-based matched cohort study involving 55 539 women diagnosed with PND during 2001-14 in Sweden and 545 567 unaffected women individually matched on age and year of conception/delivery was conducted. All women were followed up to 2020. Perinatal depression and CVD were identified from Swedish national health registers. Using multivariable Cox models, hazard ratios (HR) of any and type-specific CVD according to PND were estimated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age at the PND diagnosis was 30.8 [standard deviation (SD) 5.6] years. During the follow-up of up to 20 years (mean 10.4, SD 3.6), 3533 (6.4%) women with PND (expected number 2077) and 20 202 (3.7%) unaffected women developed CVD. Compared with matched unaffected women, women with PND had a 36% higher risk of developing CVD [adjusted HR = 1.36, 95% confidence interval (CI): 1.31-1.42], while compared with their sisters, women with PND had a 20% higher risk of CVD (adjusted HR = 1.20, 95% CI 1.07-1.34). The results were most pronounced in women without a history of psychiatric disorder (P for interaction &lt; .001). The association was observed for all CVD subtypes, with the highest HR in the case of hypertensive disease (HR = 1.50, 95% CI: 1.41-1.60), ischaemic heart disease (HR = 1.37, 95% CI: 1.13-1.65), and heart failure (HR 1.36, 95% CI: 1.06-1.74).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Women with PND are at higher risk of CVD in middle adulthood. Reproductive history, including PND, should be considered in CVD risk assessments of women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38889798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38889798</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae170>10.1093/eurheartj/ehae170</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38889798</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Donghao Lu</dc:creator>
<dc:creator>Unnur A Valdimarsdóttir</dc:creator>
<dc:creator>Dang Wei</dc:creator>
<dc:creator>Yufeng Chen</dc:creator>
<dc:creator>Ole A Andreassen</dc:creator>
<dc:creator>Fang Fang</dc:creator>
<dc:creator>Krisztina D László</dc:creator>
<dc:creator>Emma Bränn</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perinatal depression and risk of maternal cardiovascular disease: a Swedish nationwide study</dc:title>
<dc:identifier>pmid:38889798</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae170</dc:identifier>
</item>
<item>
<title>The genomic and cellular basis of biosynthetic innovation in rove beetles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38889727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>How evolution at the cellular level potentiates macroevolutionary change is central to understanding biological diversification. The >;66,000 rove beetle species (Staphylinidae) form the largest metazoan family. Combining genomic and cell type transcriptomic insights spanning the largest clade, Aleocharinae, we retrace evolution of two cell types comprising a defensive gland-a putative catalyst behind staphylinid megadiversity. We identify molecular evolutionary steps leading to benzoquinone...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 11:S0092-8674(24)00521-X. doi: 10.1016/j.cell.2024.05.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">How evolution at the cellular level potentiates macroevolutionary change is central to understanding biological diversification. The >;66,000 rove beetle species (Staphylinidae) form the largest metazoan family. Combining genomic and cell type transcriptomic insights spanning the largest clade, Aleocharinae, we retrace evolution of two cell types comprising a defensive gland-a putative catalyst behind staphylinid megadiversity. We identify molecular evolutionary steps leading to benzoquinone production by one cell type via a mechanism convergent with plant toxin release systems, and synthesis by the second cell type of a solvent that weaponizes the total secretion. This cooperative system has been conserved since the Early Cretaceous as Aleocharinae radiated into tens of thousands of lineages. Reprogramming each cell type yielded biochemical novelties enabling ecological specialization-most dramatically in symbionts that infiltrate social insect colonies via host-manipulating secretions. Our findings uncover cell type evolutionary processes underlying the origin and evolvability of a beetle chemical innovation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38889727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38889727</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.012>10.1016/j.cell.2024.05.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38889727</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Sheila A Kitchen</dc:creator>
<dc:creator>Thomas H Naragon</dc:creator>
<dc:creator>Adrian Brückner</dc:creator>
<dc:creator>Mark S Ladinsky</dc:creator>
<dc:creator>Sofia A Quinodoz</dc:creator>
<dc:creator>Jean M Badroos</dc:creator>
<dc:creator>Joani W Viliunas</dc:creator>
<dc:creator>Yuriko Kishi</dc:creator>
<dc:creator>Julian M Wagner</dc:creator>
<dc:creator>David R Miller</dc:creator>
<dc:creator>Mina Yousefelahiyeh</dc:creator>
<dc:creator>Igor A Antoshechkin</dc:creator>
<dc:creator>K Taro Eldredge</dc:creator>
<dc:creator>Stacy Pirro</dc:creator>
<dc:creator>Mitchell Guttman</dc:creator>
<dc:creator>Steven R Davis</dc:creator>
<dc:creator>Matthew L Aardema</dc:creator>
<dc:creator>Joseph Parker</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The genomic and cellular basis of biosynthetic innovation in rove beetles</dc:title>
<dc:identifier>pmid:38889727</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.012</dc:identifier>
</item>
<item>
<title>RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this study suggest that vascular cell dysfunction mediated by variants in the RNF213 locus may promote coronary vasospasm, and the presence of the risk allele could serve as a predictive factor for the prognosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 18. doi: 10.1001/jamacardio.2024.1483. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Vasospastic angina (VSA) is vasospasm of the coronary artery and is particularly prevalent in East Asian populations. However, the specific genetic architecture for VSA at genome-wide levels is not fully understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To identify genetic factors associated with VSA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a case-control genome-wide association study of VSA. Data from Biobank Japan (BBJ; enrolled patients from 2002-2008 and 2013-2018) were used, and controls without coronary artery disease (CAD) were enrolled. Patients from the BBJ were genotyped using arrays or a set of arrays. Patients recruited between 2002 and 2005 were classified within the first dataset, and those recruited between 2006 and 2008 were classified within the second dataset. To replicate the genome-wide association study in the first and second datasets, VSA cases and control samples from the latest patients in the BBJ recruited between 2013 and 2018 were analyzed in a third dataset.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Single-nucleotide variants associated with VSA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cases with VSA and controls without CAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 5720 cases (mean [SD] age, 67 [10] years; 3672 male [64.2%]) and 153 864 controls (mean [SD] age, 62 [15] years; 77 362 male [50.3%]) in 3 datasets were included in this study. The variants at the RNF213 locus showed the strongest association with VSA across the 3 datasets (odds ratio [OR], 2.34; 95% CI, 1.99-2.74; P = 4.4 × 10-25). Additionally, rs112735431, an Asian-specific rare deleterious variant (p.Arg4810Lys) experimentally shown to be associated with reduced angiogenesis and a well-known causal risk for Moyamoya disease was the most promising candidate for a causal variant explaining the association. The effect size of rs112735431 on VSA was distinct from that of other CADs. Furthermore, homozygous carriers of rs112735431 showed an association with VSA characterized by a large effect estimate (OR, 18.34; 95% CI, 5.15-65.22; P = 7.0 × 10-6), deviating from the additive model (OR, 4.35; 95% CI, 1.18-16.05; P = .03). Stratified analyses revealed that rs112735431 exhibited a stronger association in males (χ21 = 7.24; P = .007) and a younger age group (OR, 3.06; 95% CI, 2.24-4.19), corresponding to the epidemiologic features of VSA. In the registry, carriers without CAD of the risk allele rs112735431 had a strikingly high mortality rate due to acute myocardial infarction during the follow-up period (hazard ratio, 2.71; 95% CI, 1.57-4.65; P = 3.3 × 10-4). As previously reported, a possible overlap between VSA and Moyamoya disease was not found.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this study suggest that vascular cell dysfunction mediated by variants in the RNF213 locus may promote coronary vasospasm, and the presence of the risk allele could serve as a predictive factor for the prognosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888930</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1483>10.1001/jamacardio.2024.1483</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888930</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Keiko Hikino</dc:creator>
<dc:creator>Satoshi Koyama</dc:creator>
<dc:creator>Kaoru Ito</dc:creator>
<dc:creator>Yoshinao Koike</dc:creator>
<dc:creator>Masaru Koido</dc:creator>
<dc:creator>Takayoshi Matsumura</dc:creator>
<dc:creator>Ryo Kurosawa</dc:creator>
<dc:creator>Kohei Tomizuka</dc:creator>
<dc:creator>Shuji Ito</dc:creator>
<dc:creator>Xiaoxi Liu</dc:creator>
<dc:creator>Yuki Ishikawa</dc:creator>
<dc:creator>Yukihide Momozawa</dc:creator>
<dc:creator>Takayuki Morisaki</dc:creator>
<dc:creator>Yoichiro Kamatani</dc:creator>
<dc:creator>Taisei Mushiroda</dc:creator>
<dc:creator>Chikashi Terao</dc:creator>
<dc:creator>Biobank Japan Project</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>RNF213 Variants, Vasospastic Angina, and Risk of Fatal Myocardial Infarction</dc:title>
<dc:identifier>pmid:38888930</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1483</dc:identifier>
</item>
<item>
<title>Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>Ventricular septal defects are a rare complication after acute myocardial infarction with a mortality close to 100% if left untreated. However, even surgical or interventional closure is associated with a very high mortality and currently no randomized controlled trials are available addressing the optimal treatment strategy of this disease. This state-of-the-art review and clinical consensus statement will outline the diagnosis, hemodynamic consequences and treatment strategies of ventricular...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 18:ehae363. doi: 10.1093/eurheartj/ehae363. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ventricular septal defects are a rare complication after acute myocardial infarction with a mortality close to 100% if left untreated. However, even surgical or interventional closure is associated with a very high mortality and currently no randomized controlled trials are available addressing the optimal treatment strategy of this disease. This state-of-the-art review and clinical consensus statement will outline the diagnosis, hemodynamic consequences and treatment strategies of ventricular septal defects complicating acute myocardial infarction with a focus on current available evidence and a focus on major research questions to fill the gap in evidence.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae363>10.1093/eurheartj/ehae363</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888906</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Florian Schlotter</dc:creator>
<dc:creator>Kurt Huber</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Sigrun Halvorsen</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Konstantin Krychtiuk</dc:creator>
<dc:creator>Roberto Lorusso</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>Patrick A Calvert</dc:creator>
<dc:creator>Matteo Montorfano</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery</dc:title>
<dc:identifier>pmid:38888906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae363</dc:identifier>
</item>
<item>
<title>Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888905/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In both the aging and younger general population with hypertension, the nonphysician health care practitioner-led, multifaceted, intensive blood pressure intervention model could effectively and safely reduce the risk of cardiovascular disease and all-cause death.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 18. doi: 10.1001/jamacardio.2024.1449. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The sustainable effectiveness and safety of a nonphysician community health care practitioner-led intensive blood pressure intervention on cardiovascular disease have not, to the authors' knowledge, been studied, especially in the older adult population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate such a multifaceted model with a more stringent blood pressure treatment goal (&lt;130/80 mm Hg) among patients aged 60 years and older with hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a 48-month follow-up study of the China Rural Hypertension Control Project (CRHCP), an open-cluster randomized clinical trial, conducted from 2018 to 2023. Participants 60 years and older and younger than 60 years with a diagnosis of hypertension from the CRHCP trial were included for analysis. Individuals were recruited from 326 villages in rural China.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: The well-trained, nonphysician, community health care practitioner implemented a multifaceted intervention program (eg, initiation or titration of antihypertensive medications) to achieve a blood pressure level of less than 130/80 mm Hg, supervised by primary care physicians.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cardiovascular disease (a composite of myocardial infarction, stroke, heart failure requiring hospitalization, and cardiovascular disease death).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 22 386 individuals 60 years and older with hypertension and 11 609 individuals younger than 60 years with hypertension were included in the analysis. The mean (SD) age of the participants was 63.0 (9.0) years and included 20 825 females (61.3%). Among the older individuals with hypertension, a total of 11 289 patients were randomly assigned to the intervention group and 11 097 to the usual-care group. During a median (IQR) of 4.0 (4.0-4.1) years, there was a significantly lower rate of total cardiovascular disease (1133 [2.7%] vs 1433 [3.5%] per year; hazard ratio [HR], 0.75; 95% CI, 0.69-0.81; P &lt; .001) and all-cause mortality (1111 [2.5%] vs 1210 [2.8%] per year; HR, 0.90; 95% CI, 0.83-0.98; P = .01) in the intervention group than in the usual-care group. For patients younger than 60 years, the risk reductions were also significant for total cardiovascular disease (HR, 0.64; 95% CI, 0.56-0.75; P &lt; .001), stroke (HR, 0.64; 95% CI, 0.55-0.76; P &lt; .001), heart failure (HR, 0.39; 95% CI, 0.18-0.87; P = .02), and cardiovascular death (HR, 0.54; 95% CI, 0.37-0.77; P &lt; .001), with all interaction P values for age groups greater than .05. In both age categories, the incidences of injurious falls, symptomatic hypotension, syncope, and the results for kidney outcomes did not differ significantly between groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In both the aging and younger general population with hypertension, the nonphysician health care practitioner-led, multifaceted, intensive blood pressure intervention model could effectively and safely reduce the risk of cardiovascular disease and all-cause death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03527719.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888905/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888905</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1449>10.1001/jamacardio.2024.1449</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888905</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaofan Guo</dc:creator>
<dc:creator>Nanxiang Ouyang</dc:creator>
<dc:creator>Guozhe Sun</dc:creator>
<dc:creator>Naijin Zhang</dc:creator>
<dc:creator>Zhao Li</dc:creator>
<dc:creator>Xingang Zhang</dc:creator>
<dc:creator>Guangxiao Li</dc:creator>
<dc:creator>Chang Wang</dc:creator>
<dc:creator>Lixia Qiao</dc:creator>
<dc:creator>Ying Zhou</dc:creator>
<dc:creator>Zihan Chen</dc:creator>
<dc:creator>Chuning Shi</dc:creator>
<dc:creator>Songyue Liu</dc:creator>
<dc:creator>Wei Miao</dc:creator>
<dc:creator>Danxi Geng</dc:creator>
<dc:creator>Pengyu Zhang</dc:creator>
<dc:creator>Yingxian Sun</dc:creator>
<dc:creator>CRHCP Study Group</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38888905</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1449</dc:identifier>
</item>
<item>
<title>Hardware removal is a must with endocarditis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 18:ehae349. doi: 10.1093/eurheartj/ehae349. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888900</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae349>10.1093/eurheartj/ehae349</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888900</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Taylor Sirset-Becker</dc:creator>
<dc:creator>Prasad Dasi</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hardware removal is a must with endocarditis</dc:title>
<dc:identifier>pmid:38888900</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae349</dc:identifier>
</item>
<item>
<title>A Pathway to Better Blood Pressure Control</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 18. doi: 10.1001/jamacardio.2024.1463. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888898</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1463>10.1001/jamacardio.2024.1463</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888898</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel W Jones</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>A Pathway to Better Blood Pressure Control</dc:title>
<dc:identifier>pmid:38888898</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1463</dc:identifier>
</item>
<item>
<title>Ablation of persistent atrial fibrillation: never say never again</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 18:ehae374. doi: 10.1093/eurheartj/ehae374. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888896</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae374>10.1093/eurheartj/ehae374</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888896</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Michelle Samuel</dc:creator>
<dc:creator>Michiel Rienstra</dc:creator>
<dc:creator>Isabelle C Van Gelder</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ablation of persistent atrial fibrillation: never say never again</dc:title>
<dc:identifier>pmid:38888896</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae374</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 11;149(24):1921-1926. doi: 10.1161/CIRCULATIONAHA.124.070462. Epub 2024 Jun 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888589</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070462>10.1161/CIRCULATIONAHA.124.070462</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888589</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38888589</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070462</dc:identifier>
</item>
<item>
<title>The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38888535/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07407-2. doi: 10.1016/j.jacc.2024.05.036. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38888535/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38888535</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.036>10.1016/j.jacc.2024.05.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38888535</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Anuradha Lala</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Carlos G Santos-Gallego</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?</dc:title>
<dc:identifier>pmid:38888535</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.036</dc:identifier>
</item>
<item>
<title>A metabolomics pipeline highlights microbial metabolism in bloodstream infections</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885650/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>The growth of antimicrobial resistance (AMR) highlights an urgent need to identify bacterial pathogenic functions that may be targets for clinical intervention. Although severe infections profoundly alter host metabolism, prior studies have largely ignored microbial metabolism in this context. Here, we describe an iterative, comparative metabolomics pipeline to uncover microbial metabolic features in the complex setting of a host and apply it to investigate gram-negative bloodstream infection...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 11:S0092-8674(24)00579-8. doi: 10.1016/j.cell.2024.05.035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The growth of antimicrobial resistance (AMR) highlights an urgent need to identify bacterial pathogenic functions that may be targets for clinical intervention. Although severe infections profoundly alter host metabolism, prior studies have largely ignored microbial metabolism in this context. Here, we describe an iterative, comparative metabolomics pipeline to uncover microbial metabolic features in the complex setting of a host and apply it to investigate gram-negative bloodstream infection (BSI) in patients. We find elevated levels of bacterially derived acetylated polyamines during BSI and discover the enzyme responsible for their production (SpeG). Blocking SpeG activity reduces bacterial proliferation and slows pathogenesis. Reduction of SpeG activity also enhances bacterial membrane permeability and increases intracellular antibiotic accumulation, allowing us to overcome AMR in culture and in vivo. This study highlights how tools to study pathogen metabolism in the natural context of infection can reveal and prioritize therapeutic strategies for addressing challenging infections.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885650/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885650</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.035>10.1016/j.cell.2024.05.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885650</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jared R Mayers</dc:creator>
<dc:creator>Jack Varon</dc:creator>
<dc:creator>Ruixuan R Zhou</dc:creator>
<dc:creator>Martin Daniel-Ivad</dc:creator>
<dc:creator>Courtney Beaulieu</dc:creator>
<dc:creator>Amrisha Bholse</dc:creator>
<dc:creator>Nathaniel R Glasser</dc:creator>
<dc:creator>Franziska M Lichtenauer</dc:creator>
<dc:creator>Julie Ng</dc:creator>
<dc:creator>Mayra Pinilla Vera</dc:creator>
<dc:creator>Curtis Huttenhower</dc:creator>
<dc:creator>Mark A Perrella</dc:creator>
<dc:creator>Clary B Clish</dc:creator>
<dc:creator>Sihai D Zhao</dc:creator>
<dc:creator>Rebecca M Baron</dc:creator>
<dc:creator>Emily P Balskus</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A metabolomics pipeline highlights microbial metabolism in bloodstream infections</dc:title>
<dc:identifier>pmid:38885650</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.035</dc:identifier>
</item>
<item>
<title>Legend of MERLIN and the Quest for Cardiac Lineage Commitment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885302/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 18;149(25):1980-1981. doi: 10.1161/CIRCULATIONAHA.123.065901. Epub 2024 Jun 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885302/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885302</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11185273/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">PMC11185273</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065901>10.1161/CIRCULATIONAHA.123.065901</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885302</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rich Gang Li</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Legend of MERLIN and the Quest for Cardiac Lineage Commitment</dc:title>
<dc:identifier>pmid:38885302</dc:identifier>
<dc:identifier>pmc:PMC11185273</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065901</dc:identifier>
</item>
<item>
<title>Advanced Cardiac Patches for the Treatment of Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885303/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>Myocardial infarction is a cardiovascular disease characterized by a high incidence rate and mortality. It leads to various cardiac pathophysiological changes, including ischemia/reperfusion injury, inflammation, fibrosis, and ventricular remodeling, which ultimately result in heart failure and pose a significant threat to global health. Although clinical reperfusion therapies and conventional pharmacological interventions improve emergency survival rates and short-term prognoses, they are still...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 18;149(25):2002-2020. doi: 10.1161/CIRCULATIONAHA.123.067097. Epub 2024 Jun 17.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Myocardial infarction is a cardiovascular disease characterized by a high incidence rate and mortality. It leads to various cardiac pathophysiological changes, including ischemia/reperfusion injury, inflammation, fibrosis, and ventricular remodeling, which ultimately result in heart failure and pose a significant threat to global health. Although clinical reperfusion therapies and conventional pharmacological interventions improve emergency survival rates and short-term prognoses, they are still limited in providing long-lasting improvements in cardiac function or reversing pathological progression. Recently, cardiac patches have gained considerable attention as a promising therapy for myocardial infarction. These patches consist of scaffolds or loaded therapeutic agents that provide mechanical reinforcement, synchronous electrical conduction, and localized delivery within the infarct zone to promote cardiac restoration. This review elucidates the pathophysiological progression from myocardial infarction to heart failure, highlighting therapeutic targets and various cardiac patches. The review considers the primary scaffold materials, including synthetic, natural, and conductive materials, and the prevalent fabrication techniques and optimal properties of the patch, as well as advanced delivery strategies. Last, the current limitations and prospects of cardiac patch research are considered, with the goal of shedding light on innovative products poised for clinical application.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885303/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885303</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067097>10.1161/CIRCULATIONAHA.123.067097</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885303</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Tailuo Liu</dc:creator>
<dc:creator>Ying Hao</dc:creator>
<dc:creator>Zixuan Zhang</dc:creator>
<dc:creator>Hao Zhou</dc:creator>
<dc:creator>Shiqin Peng</dc:creator>
<dc:creator>Dingyi Zhang</dc:creator>
<dc:creator>Ka Li</dc:creator>
<dc:creator>Yuwen Chen</dc:creator>
<dc:creator>Mao Chen</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Advanced Cardiac Patches for the Treatment of Myocardial Infarction</dc:title>
<dc:identifier>pmid:38885303</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067097</dc:identifier>
</item>
<item>
<title>Response by Jeong et al to Letter Regarding Article, "Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885301/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 18;149(25):e1417. doi: 10.1161/CIRCULATIONAHA.124.069374. Epub 2024 Jun 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885301</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069374>10.1161/CIRCULATIONAHA.124.069374</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885301</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>In-Seok Jeong</dc:creator>
<dc:creator>Min Chul Kim</dc:creator>
<dc:creator>Yongwhan Lim</dc:creator>
<dc:creator>Youngkeun Ahn</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Jeong et al to Letter Regarding Article, "Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:38885301</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069374</dc:identifier>
</item>
<item>
<title>Numbing the Heart to Death: A Cautionary Tale About an In-Vogue Preoperative Analgesic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885300/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 18;149(25):2021-2025. doi: 10.1161/CIRCULATIONAHA.123.068294. Epub 2024 Jun 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885300/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885300</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068294>10.1161/CIRCULATIONAHA.123.068294</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885300</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Benjamin B Holmes</dc:creator>
<dc:creator>Katherine T Murray</dc:creator>
<dc:creator>William G Stevenson</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Numbing the Heart to Death: A Cautionary Tale About an In-Vogue Preoperative Analgesic</dc:title>
<dc:identifier>pmid:38885300</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068294</dc:identifier>
</item>
<item>
<title>Trajectories in Cardiac Aging: Journey to the Crossroads of Inflammation and Metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885299/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 18;149(25):1935-1937. doi: 10.1161/CIRCULATIONAHA.123.065116. Epub 2024 Jun 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885299/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885299</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065116>10.1161/CIRCULATIONAHA.123.065116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885299</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Geneviève Derumeaux</dc:creator>
<dc:creator>Daigo Sawaki</dc:creator>
<dc:creator>Gabor Czibik</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Trajectories in Cardiac Aging: Journey to the Crossroads of Inflammation and Metabolism</dc:title>
<dc:identifier>pmid:38885299</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065116</dc:identifier>
</item>
<item>
<title>Letter by Jha Regarding Article, "Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885298/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 18;149(25):e1415-e1416. doi: 10.1161/CIRCULATIONAHA.123.068105. Epub 2024 Jun 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885298/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885298</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068105>10.1161/CIRCULATIONAHA.123.068105</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885298</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ajay Kumar Jha</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Jha Regarding Article, "Early Left Ventricular Unloading or Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation: The EARLY-UNLOAD Randomized Clinical Trial"</dc:title>
<dc:identifier>pmid:38885298</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068105</dc:identifier>
</item>
<item>
<title>Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38885297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 18;149(25):2026-2028. doi: 10.1161/CIRCULATIONAHA.124.069479. Epub 2024 Jun 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38885297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38885297</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11185269/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">PMC11185269</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069479>10.1161/CIRCULATIONAHA.124.069479</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38885297</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jwan A Naser</dc:creator>
<dc:creator>Atsushi Tada</dc:creator>
<dc:creator>Tomonari Harada</dc:creator>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:creator>Rickey E Carter</dc:creator>
<dc:creator>Jeffrey M Testani</dc:creator>
<dc:creator>Michael D Jensen</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:38885297</dc:identifier>
<dc:identifier>pmc:PMC11185269</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069479</dc:identifier>
</item>
<item>
<title>Deep Learning for Echo Analysis, Tracking, and Evaluation of Mitral Regurgitation (DELINEATE-MR)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38881496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This end-to-end DL system can intake entire echocardiogram studies to accurately classify MR severity and may be useful in helping clinicians refine MR assessments.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 17. doi: 10.1161/CIRCULATIONAHA.124.068996. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Artificial intelligence, particularly deep learning (DL), has immense potential to improve the interpretation of transthoracic echocardiography (TTE). Mitral regurgitation (MR) is the most common valvular heart disease and presents unique challenges for DL, including the integration of multiple video-level assessments into a final study-level classification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A novel DL system was developed to intake complete TTEs, identify color MR Doppler videos, and determine MR severity on a 4-step ordinal scale (none/trace, mild, moderate, and severe) using the reading cardiologist as a reference standard. This DL system was tested in internal and external test sets with performance assessed by agreement with the reading cardiologist, weighted κ, and area under the receiver-operating characteristic curve for binary classification of both moderate or greater and severe MR. In addition to the primary 4-step model, a 6-step MR assessment model was studied with the addition of the intermediate MR classes of mild-moderate and moderate-severe with performance assessed by both exact agreement and ±1 step agreement with the clinical MR interpretation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 61 689 TTEs were split into train (n=43 811), validation (n=8891), and internal test (n=8987) sets with an additional external test set of 8208 TTEs. The model had high performance in MR classification in internal (exact accuracy, 82%; κ=0.84; area under the receiver-operating characteristic curve, 0.98 for moderate/severe MR) and external test sets (exact accuracy, 79%; κ=0.80; area under the receiver-operating characteristic curve, 0.98 for moderate or greater MR). Most (63% internal and 66% external) misclassification disagreements were between none/trace and mild MR. MR classification accuracy was slightly higher using multiple TTE views (accuracy, 82%) than with only apical 4-chamber views (accuracy, 80%). In subset analyses, the model was accurate in the classification of both primary and secondary MR with slightly lower performance in cases of eccentric MR. In the analysis of the 6-step classification system, the exact accuracy was 80% and 76% with a ±1 step agreement of 99% and 98% in the internal and external test set, respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This end-to-end DL system can intake entire echocardiogram studies to accurately classify MR severity and may be useful in helping clinicians refine MR assessments.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38881496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38881496</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068996>10.1161/CIRCULATIONAHA.124.068996</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38881496</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Aaron Long</dc:creator>
<dc:creator>Christopher M Haggerty</dc:creator>
<dc:creator>Joshua Finer</dc:creator>
<dc:creator>Dustin Hartzel</dc:creator>
<dc:creator>Linyuan Jing</dc:creator>
<dc:creator>Azadeh Keivani</dc:creator>
<dc:creator>Christopher Kelsey</dc:creator>
<dc:creator>Daniel Rocha</dc:creator>
<dc:creator>Jeffrey Ruhl</dc:creator>
<dc:creator>David vanMaanen</dc:creator>
<dc:creator>Gil Metser</dc:creator>
<dc:creator>Eamon Duffy</dc:creator>
<dc:creator>Thomas Mawson</dc:creator>
<dc:creator>Mathew Maurer</dc:creator>
<dc:creator>Andrew J Einstein</dc:creator>
<dc:creator>Ashley Beecy</dc:creator>
<dc:creator>Deepa Kumaraiah</dc:creator>
<dc:creator>Shunichi Homma</dc:creator>
<dc:creator>Qi Liu</dc:creator>
<dc:creator>Vratika Agarwal</dc:creator>
<dc:creator>Mark Lebehn</dc:creator>
<dc:creator>Martin Leon</dc:creator>
<dc:creator>Rebecca Hahn</dc:creator>
<dc:creator>Pierre Elias</dc:creator>
<dc:creator>Timothy J Poterucha</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Deep Learning for Echo Analysis, Tracking, and Evaluation of Mitral Regurgitation (DELINEATE-MR)</dc:title>
<dc:identifier>pmid:38881496</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068996</dc:identifier>
</item>
<item>
<title>Unraveling the Mechanisms of Valvular Heart Disease to Identify Medical Therapy Targets: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38881493/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240619121131&amp;v=2.18.0.post9+e462414
      <description>Valvular heart disease is a common cause of morbidity and mortality worldwide and has no effective medical therapy. Severe disease is managed with valve replacement procedures, which entail high health care-related costs and postprocedural morbidity and mortality. Robust ongoing research programs have elucidated many important molecular pathways contributing to primary valvular heart disease. However, there remain several key challenges inherent in translating research on valvular heart disease...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 17. doi: 10.1161/CIR.0000000000001254. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Valvular heart disease is a common cause of morbidity and mortality worldwide and has no effective medical therapy. Severe disease is managed with valve replacement procedures, which entail high health care-related costs and postprocedural morbidity and mortality. Robust ongoing research programs have elucidated many important molecular pathways contributing to primary valvular heart disease. However, there remain several key challenges inherent in translating research on valvular heart disease to viable molecular targets that can progress through the clinical trials pathway and effectively prevent or modify the course of these common conditions. In this scientific statement, we review the basic cellular structures of the human heart valves and discuss how these structures change in primary valvular heart disease. We focus on the most common primary valvular heart diseases, including calcific aortic stenosis, bicuspid aortic valves, mitral valve prolapse, and rheumatic heart disease, and outline the fundamental molecular discoveries contributing to each. We further outline potential therapeutic molecular targets for primary valvular heart disease and discuss key knowledge gaps that might serve as future research priorities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38881493/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240619121131&v=2.18.0.post9+e462414">38881493</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001254>10.1161/CIR.0000000000001254</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38881493</guid>
<pubDate>Mon, 17 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Aeron M Small</dc:creator>
<dc:creator>Katherine E Yutzey</dc:creator>
<dc:creator>Bryce A Binstadt</dc:creator>
<dc:creator>Kaitlin Voigts Key</dc:creator>
<dc:creator>Nabila Bouatia-Naji</dc:creator>
<dc:creator>David Milan</dc:creator>
<dc:creator>Elena Aikawa</dc:creator>
<dc:creator>Catherine M Otto</dc:creator>
<dc:creator>Cynthia St Hilaire</dc:creator>
<dc:creator>American Heart Association Council on Genomic and Precision Medicine Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-06-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unraveling the Mechanisms of Valvular Heart Disease to Identify Medical Therapy Targets: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38881493</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001254</dc:identifier>
</item>





























</channel>
</rss>